article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7% from 1,401 estimated PET scans per system in 2022 to 1,495 in 2023. Davin Korstjens. physicians reading PET scans per site.

PET Scan 115
article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Treatment paradigm shifting for men with prostate cancer

AuntMinnie

New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. I can’t emphasize that enough.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging. However, few freestanding theranostics centers exist today. Hope added.

article thumbnail

Photo Gallery of Radiology Technology, Highlights from RSNA 2023

Imaging Technology

26-30, 2023.

article thumbnail

SNMMI: Y-90-FAPI-46 more effective for advanced sarcoma

AuntMinnie

An emerging radioligand therapy could be particularly effective for controlling advanced sarcoma compared to other cancers, according to research presented June 8 in a Young Investigator Award session at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Toronto.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.